UB-312 + Placebo

Phase 1Completed

2 views this week 0 watching💤 Quiet

Interest: 19/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Parkinson's Disease

Conditions

Parkinson's Disease, Parkinsonism

Trial Timeline

Aug 29, 2019 → Mar 1, 2023

NCT ID

NCT04075318

About UB-312 + Placebo

UB-312 + Placebo is a phase 1 stage product being developed by Vaxxinity for Parkinson's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04075318. Target conditions include Parkinson's Disease, Parkinsonism.

What happened to similar drugs?

20 of 20 similar drugs in Parkinson's Disease were approved

Approved (20) Terminated (3) Active (0)

✅Lemborexant + placeboEisaiApproved

✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved

✅Carbidopa/levodopa/entacaponeNovartisApproved

✅Carbidopa/levodopa/entacapone + Immediate release carbidopa/levodopaNovartisApproved

✅carbidopa/levodopa + Carbidopa/Levodopa/EntacaponeNovartisApproved

✅carbidopa, levodopa, entacaponeNovartisApproved

✅Levodopa/carbidopa/entacapone + Levodopa/carbidopaNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04075318	Phase 1	Completed	Aug 29, 2019	Mar 1, 2023	Parkinson's Disease

Competing Products

20 competing products in Parkinson's Disease

See all competitors

Product	Company	Stage	Hype Score
NAV5001 + DaTscan	Navidea Biopharmaceuticals	Phase 3	22
piclozotan + 0.9% sodium chloride (normal saline)	Daiichi Sankyo	Phase 2	35
E2007	Eisai	Phase 3	32
ARICEPT	Eisai	Phase 3	40
Perampanel	Eisai	Phase 3	32
GPI 1485	Eisai	Phase 2	35
E2007	Eisai	Phase 3	40
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo	Eisai	Phase 3	40
perampanel + placebo	Eisai	Phase 2	27
Lemborexant + placebo	Eisai	Approved	50
Placebo + E2007 + E2007	Eisai	Phase 3	32
E2007 + E2007 + E2007	Eisai	Phase 2	35
E2007	Eisai	Phase 2	35
E2007	Eisai	Phase 2	27
E2007	Eisai	Phase 2	27
2 mg perampanel + 4 mg perampanel + placebo comparator	Eisai	Phase 3	40
Istradefylline (KW-6002)	Kyowa Kirin	Phase 2	35
Istradefylline 20 mg or 40 mg	Kyowa Kirin	Phase 3	40
Istradefylline (KW-6002)	Kyowa Kirin	Phase 3	40
Perampanel	Eisai	Phase 2	27